arn-75039
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 9, 2023 (NCT05735249)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Mammarenavirus choriomeningitidisINHIBITOR
Mammarenavirus choriomeningitidis inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06911242 | Phase 1 | Mar 17, 2025 | Arisan Therapeutics, Inc. |
| NCT05735249 | Phase 1 | Jan 9, 2023 | Arisan Therapeutics, Inc., Battelle, Department of Defense |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arisan Therapeutics, Inc. | For profit | 2 | 2 | 1 | 2023 |
| Battelle | For profit | 1 | 0 | 1 | 2023 |
| Department of Defense | Government | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1